Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia

For patients with optimally treated chronic myeloid leukemia (CML), discontinuation of tyrosine kinase inhibitor (TKI) therapy can lead to treatment-free remission. In previous trials, TKI discontinuation has been associated with increased musculoskeletal pain in some patients (“withdrawal syndrome”...

Descripción completa

Detalles Bibliográficos
Autores principales: Flynn, Kathryn E., Atallah, Ehab, Lin, Li, Shah, Neil P., Silver, Richard T., Larson, Richard A., Pinilla-Ibarz, Javier, Thompson, James E., Oehler, Vivian G., Radich, Jerald P., Kota, Vamsi, Mauro, Michael J., Schiffer, Charles A., Cortes, Jorge, Weinfurt, Kevin P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article - Chronic Myeloid Leukemia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614525/
https://www.ncbi.nlm.nih.gov/pubmed/35511672
http://dx.doi.org/10.3324/haematol.2021.280377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614525/
https://www.ncbi.nlm.nih.gov/pubmed/35511672
http://dx.doi.org/10.3324/haematol.2021.280377

Ejemplares similares